RobertBSimsMD

PubMed

• 30 citations
  Combining Immunotherapy and Radiation for Prostate Cancer
  Steven E. Finkelstein, Sharon Salenius, Constantine A. Mantz, N. Shore, Eduardo Fernandez, Jesse Shulman, Francisco A. Myslicki, Andre M. Agassi, Yosef Rotterman, Todd...> ;Clinical Genitourinary Cancer. 2015 Feb 1
• 213 citations
  Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
  Lawrence Fong, Peter R. Carroll, Vivian Weinberg, Stephen Chan, Jera Lewis, John M. Corman, Christopher L. Amling, Robert A. Stephenson, Jeff Simko, Nadeem A. Sheikh, ...> ;Journal of the National Cancer Institute. 2014 Nov 1
• 42 citations
  A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
  Douglas G. McNeel, Thomas A. Gardner, Celestia S. Higano, Philip W. Kantoff, Eric J. Small, Mark H. Wener, Robert B. Sims, Todd DeVries, Nadeem A. Sheikh, Robert Dreicer> ;Cancer Immunology Research. 2014 Oct 1
• 6 citations
  The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer
  Vladimir Mouraviev, Neil Mariados, David M. Albala, Raoul S. Concepcion, Neal D. Shore, Robert B. Sims, Mark Emberton, Christopher Michael Pieczonka> ;Reviews in Urology. 2014 Jan 1
• 233 citations
  Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treat...
  Paul F. Schellhammer, Gerald W. Chodak, James Boyd Whitmore, Robert B. Sims, Mark W. Frohlich, Philip W. Kantoff> ;Urology. 2013 Jun 1
• 11 citations
  An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resist...
  Robert C. Flanigan, Anthony J. Polcari, Neil Shore, Thomas H. Price, Robert B. Sims, Johnathan Maher, James Boyd Whitmore, John M. Corman> ;The Journal of Urology. 2013 Feb 1
• 42 citations
  Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
  Robert B. Sims> ;Vaccine. 2012 Jun 19
• Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer.
  Fong L, Weinberg VK, Corman JM, Amling CL, Stephenson RA, Formaker C, Chan SE, Simko J, Sims RB, Carroll P, Small EJ> ;J. Clin. Oncol.. 2012-02-10
• 41 citations
  Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
  Simon J. Hall, Laurence Klotz, Allan J. Pantuck, Daniel J. George, James Boyd Whitmore, Mark W. Frohlich, Robert B. Sims> ;The Journal of Urology. 2011 Sep 1
• 4 citations
  Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
  Robert B. Sims> ;Journal of Cancer. 2011 Jun 15
• 3901 citations
  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Philip W. Kantoff, Celestia S. Higano, N. Shore, E. Roy Berger, Eric J. Small, David F. Penson, Charles H. Redfern, Anna C. Ferrari, Robert Dreicer, Robert B. Sims, Yi...> ;The New England Journal of Medicine. 2010 Jul 23
• 54 citations
  A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
  Prema P. Peethambaram, Michelle E. Melisko, Kristine Rinn, Steven R. Alberts, Nicole M. Provost, Lori A. Jones, Robert B. Sims, Lisa R. C. Lin, Mark W. Frohlich, John ...> ;Clinical Cancer Research. 2009 Sep 15
• 54 citations
  Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 –Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activit...
  John W. Park, Michelle E. Melisko, Laura J. Esserman, Lori A. Jones, Jami B. Wollan, Robert B. Sims> ;Journal of Clinical Oncology. 2007 Aug 20
• 17 citations
  Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation
  Robert S. Svatek, Robert Brownell Sims, J. Kyle Anderson, Khaled F. Abdel-Aziz, Jeffrey A. Cadeddu> ;Urology. 2006 Mar 1
• 18 citations
  Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein
  Andres Forero-Torres, Sui Shen, Hazel B. Breitz, Robert B. Sims, Don B. Axworthy, M. B. Khazaeli, Kuang-Ho Chen, I. Percent, Stephen Besh, Albert F. LoBuglio> ;Cancer Biotherapy & Radiopharmaceuticals. 2005 Aug 22
• 106 citations
  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
  Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz...> ;Blood. 2004 Jul 1
• 167 citations
  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to...
  Bruno Calabretta, Robert B. Sims, Mauro Valtieri, Daniele Caracciolo, Cezary Szczylik, Donatella Venturelli, Mariusz Z. Ratajczak, Miloslov Beran, Alan M. Gewirtz> ;Proceedings of the National Academy of Sciences of the United States of America. 1991 Mar 15
• 175 citations
  G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb.
  Alan M. Gewirtz, Giovanni Anfossi, Donatella Venturelli, Susanna Valpreda, Robert B. Sims, Bruno Calabretta> ;Science. 1989 Jul 14
• Join now to see all